REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 167 filers reported holding REATA PHARMACEUTICALS INC in Q3 2019. The put-call ratio across all filers is 2.04 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $46,055,332 | +55.9% | 451,700 | +39.0% | 0.24% | +46.6% |
| Q1 2023 | $29,549,000 | +134.3% | 325,000 | -2.1% | 0.16% | +117.3% |
| Q4 2022 | $12,612,680 | -17.7% | 332,000 | +342.7% | 0.08% | -27.2% |
| Q4 2019 | $15,332,000 | +4.9% | 75,000 | -58.8% | 0.10% | -6.4% |
| Q3 2019 | $14,618,000 | -80.6% | 182,060 | -77.2% | 0.11% | -77.6% |
| Q2 2019 | $75,480,000 | +17.7% | 800,000 | +6.7% | 0.49% | +1.9% |
| Q1 2019 | $64,103,000 | +63.2% | 750,000 | +7.1% | 0.48% | +67.4% |
| Q4 2018 | $39,270,000 | -28.7% | 700,000 | +3.9% | 0.29% | -11.4% |
| Q3 2018 | $55,065,000 | – | 673,500 | – | 0.32% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CPMG Inc | 2,896,901 | $291,457,000 | 32.14% |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 46,646 | $4,693,000 | 5.31% |
| Ikarian Capital, LLC | 471,400 | $47,423,000 | 3.34% |
| Duquesne Family Office | 695,033 | $69,927,000 | 2.27% |
| Camber Capital Management LP | 685,000 | $68,918,000 | 2.12% |
| LBJ Family Wealth Advisors, Ltd. | 30,359 | $3,054,000 | 1.82% |
| MADDEN SECURITIES Corp | 33,127 | $3,333,000 | 1.80% |
| Biondo Investment Advisors, LLC | 104,120 | $10,475,000 | 1.80% |
| Tolleson Wealth Management, Inc. | 60,750 | $6,112,000 | 1.73% |
| Keel Point, LLC | 97,074 | $9,767,000 | 1.26% |